Inclusion of fenofibrate in a series of mesoporous silicas using microwave irradiation

Laura J. Waters, Talib Hussain, Gareth Parkes, John P. Hanrahan, Joseph M. Tobin

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

A selection of porous silicas were combined with a model drug using a recently developed, controlled microwave heating process to determine if the application of microwave irradiation could enhance subsequent drug release. Five mesoporous silica types were investigated (core shell, core shell rehydrox, SBA-15, silica gel, SYLOID®) and, for comparison, one non-porous silica (stober). These were formulated using a tailored microwave heating method at drug/excipient ratios of 1:1, 1:3 and 1:5. In addition, all experiments were performed both in the presence and absence of water, used as a fluidising media to aid interaction between drug and support, and compared with results obtained using more traditional heating methods. All formulations were then characterised using differential scanning calorimetry (DSC), powder X-ray diffraction (XRD), scanning electron microscopy (SEM) and Fourier transformation infrared spectroscopy (FT-IR). Pharmaceutical performance was investigated using in vitro drug release studies. A significant enhancement in the release profile of fenofibrate was observed for formulations prepared using microwave heating in the absence of water for five of the six silica based formulations. Of all the formulations analysed, the greatest extent of drug release within the experimental 30 min was the 1:5 core shell rehydrox achieving a total of 86.6 ± 2.8%. The non-porous (stober) particles did not exhibit an increased release of the drug under any experimental conditions studied. This anomaly is thought to be a result of the comparatively small surface area of the silica particles, thus preventing the adsorption of drug molecules.

Original languageEnglish
Pages (from-to)936-941
Number of pages6
JournalEuropean Journal of Pharmaceutics and Biopharmaceutics
Volume85
Issue number3 PART B
Early online date13 Aug 2013
DOIs
Publication statusPublished - Nov 2013

Fingerprint

Fenofibrate
Microwaves
Silicon Dioxide
Heating
Pharmaceutical Preparations
Water
Excipients
Silica Gel
Differential Scanning Calorimetry
Drug Interactions
X-Ray Diffraction
Electron Scanning Microscopy
Powders
Adsorption
Spectrum Analysis
Drug Liberation

Cite this

@article{6cdae937697048a9b973dfe4a6289474,
title = "Inclusion of fenofibrate in a series of mesoporous silicas using microwave irradiation",
abstract = "A selection of porous silicas were combined with a model drug using a recently developed, controlled microwave heating process to determine if the application of microwave irradiation could enhance subsequent drug release. Five mesoporous silica types were investigated (core shell, core shell rehydrox, SBA-15, silica gel, SYLOID{\circledR}) and, for comparison, one non-porous silica (stober). These were formulated using a tailored microwave heating method at drug/excipient ratios of 1:1, 1:3 and 1:5. In addition, all experiments were performed both in the presence and absence of water, used as a fluidising media to aid interaction between drug and support, and compared with results obtained using more traditional heating methods. All formulations were then characterised using differential scanning calorimetry (DSC), powder X-ray diffraction (XRD), scanning electron microscopy (SEM) and Fourier transformation infrared spectroscopy (FT-IR). Pharmaceutical performance was investigated using in vitro drug release studies. A significant enhancement in the release profile of fenofibrate was observed for formulations prepared using microwave heating in the absence of water for five of the six silica based formulations. Of all the formulations analysed, the greatest extent of drug release within the experimental 30 min was the 1:5 core shell rehydrox achieving a total of 86.6 ± 2.8{\%}. The non-porous (stober) particles did not exhibit an increased release of the drug under any experimental conditions studied. This anomaly is thought to be a result of the comparatively small surface area of the silica particles, thus preventing the adsorption of drug molecules.",
keywords = "Core shell silica, Drug release, Enhanced release, Fenofibrate, Microwave irradiation, Porous silica",
author = "Waters, {Laura J.} and Talib Hussain and Gareth Parkes and Hanrahan, {John P.} and Tobin, {Joseph M.}",
year = "2013",
month = "11",
doi = "10.1016/j.ejpb.2013.08.002",
language = "English",
volume = "85",
pages = "936--941",
journal = "European Journal of Pharmaceutics and Biopharmaceutics",
issn = "0939-6411",
publisher = "Elsevier",
number = "3 PART B",

}

Inclusion of fenofibrate in a series of mesoporous silicas using microwave irradiation. / Waters, Laura J.; Hussain, Talib; Parkes, Gareth; Hanrahan, John P.; Tobin, Joseph M.

In: European Journal of Pharmaceutics and Biopharmaceutics, Vol. 85, No. 3 PART B, 11.2013, p. 936-941.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Inclusion of fenofibrate in a series of mesoporous silicas using microwave irradiation

AU - Waters, Laura J.

AU - Hussain, Talib

AU - Parkes, Gareth

AU - Hanrahan, John P.

AU - Tobin, Joseph M.

PY - 2013/11

Y1 - 2013/11

N2 - A selection of porous silicas were combined with a model drug using a recently developed, controlled microwave heating process to determine if the application of microwave irradiation could enhance subsequent drug release. Five mesoporous silica types were investigated (core shell, core shell rehydrox, SBA-15, silica gel, SYLOID®) and, for comparison, one non-porous silica (stober). These were formulated using a tailored microwave heating method at drug/excipient ratios of 1:1, 1:3 and 1:5. In addition, all experiments were performed both in the presence and absence of water, used as a fluidising media to aid interaction between drug and support, and compared with results obtained using more traditional heating methods. All formulations were then characterised using differential scanning calorimetry (DSC), powder X-ray diffraction (XRD), scanning electron microscopy (SEM) and Fourier transformation infrared spectroscopy (FT-IR). Pharmaceutical performance was investigated using in vitro drug release studies. A significant enhancement in the release profile of fenofibrate was observed for formulations prepared using microwave heating in the absence of water for five of the six silica based formulations. Of all the formulations analysed, the greatest extent of drug release within the experimental 30 min was the 1:5 core shell rehydrox achieving a total of 86.6 ± 2.8%. The non-porous (stober) particles did not exhibit an increased release of the drug under any experimental conditions studied. This anomaly is thought to be a result of the comparatively small surface area of the silica particles, thus preventing the adsorption of drug molecules.

AB - A selection of porous silicas were combined with a model drug using a recently developed, controlled microwave heating process to determine if the application of microwave irradiation could enhance subsequent drug release. Five mesoporous silica types were investigated (core shell, core shell rehydrox, SBA-15, silica gel, SYLOID®) and, for comparison, one non-porous silica (stober). These were formulated using a tailored microwave heating method at drug/excipient ratios of 1:1, 1:3 and 1:5. In addition, all experiments were performed both in the presence and absence of water, used as a fluidising media to aid interaction between drug and support, and compared with results obtained using more traditional heating methods. All formulations were then characterised using differential scanning calorimetry (DSC), powder X-ray diffraction (XRD), scanning electron microscopy (SEM) and Fourier transformation infrared spectroscopy (FT-IR). Pharmaceutical performance was investigated using in vitro drug release studies. A significant enhancement in the release profile of fenofibrate was observed for formulations prepared using microwave heating in the absence of water for five of the six silica based formulations. Of all the formulations analysed, the greatest extent of drug release within the experimental 30 min was the 1:5 core shell rehydrox achieving a total of 86.6 ± 2.8%. The non-porous (stober) particles did not exhibit an increased release of the drug under any experimental conditions studied. This anomaly is thought to be a result of the comparatively small surface area of the silica particles, thus preventing the adsorption of drug molecules.

KW - Core shell silica

KW - Drug release

KW - Enhanced release

KW - Fenofibrate

KW - Microwave irradiation

KW - Porous silica

UR - http://www.scopus.com/inward/record.url?scp=84889084784&partnerID=8YFLogxK

U2 - 10.1016/j.ejpb.2013.08.002

DO - 10.1016/j.ejpb.2013.08.002

M3 - Article

VL - 85

SP - 936

EP - 941

JO - European Journal of Pharmaceutics and Biopharmaceutics

JF - European Journal of Pharmaceutics and Biopharmaceutics

SN - 0939-6411

IS - 3 PART B

ER -